Novavax publishes preliminary findings for COVID-19 Vaccine candidate
Novavax has published their preliminary findings for the Nucleus Network administered clinical trial of their SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine candidate in the New England Journal of Medicine.
Preliminary results of the Novavax SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine candidate have been published in the New England Journal of Medicine.
The report states that "At 35 days, NVX-CoV2373 appeared to be safe, and it elicited immune responses that exceeded levels in Covid-19 convalescent serum. The Matrix-M1 adjuvant induced CD4+ T-cell responses that were biased toward a Th1 phenotype."
While there is still a long way to go before the trials are complete, this preliminary finding offers some encouragement that a safe and effective vaccine can be found.
The article can be viewed on the New England Journal of Medicine site via this link. Pelase be aware that the paper remains copyright of Massachusetts Medical Society, 2020. Beyond any personal use, readers are instructed to source the original file from Massachusetts Medical Society. Nucleus Network thanks the Massachusetts Medical Society for the reproduction of this paper in the interests of medical research.
The report can be accessed directly on the New England Journal of Medicine website, or downloaded via the button below.